title: Effects of montelukast on the healing of ischemic colon anastomoses.
abstract: BACKGROUND
  The aim of this study was to examine whether treatment with montelukast, a selective leukotriene antagonist, would affect anastomotic healing in a reperfused colon rat model with remote ischemia/reperfusion injury.
  
  
  METHODS
  Rats (n = 12 per group) were intraperitoneally administered normal saline or 10 mg/kg montelukast sodium 60 minutes before and for 5 days after surgery. Ischemia was induced for 45 minutes through superior mesenteric artery occlusion. A left colon anastomosis was made. Blood and perianastomotic tissue samples were obtained on postoperative day 5.
  
  
  RESULTS
  Mean anastomotic bursting pressures of the control and montelukast groups were 159.17 ± 29.99 and 216.67 ± 26.40, respectively (P < .001). Compared with saline, montelukast treatment increased the mean tissue hydroxyproline level (2.46 ± .30 vs 3.61 ± .33 μmol/L) and decreased tissue caspase-3 activity (36.06 ± 5.72 vs 21.78 ± 3.87) and malondialdehyde levels (3.43 ± .34 vs 2.29 ± .34 nmol/g) (P < .001 for all). Other plasma markers of injury also showed differences.
  
  
  CONCLUSIONS
  Montelukast prevented ischemia/reperfusion-induced damage in a rat model of colonic anastomotic wound healing.
authors.affiliation: Department of General Surgery, Bagcilar Training and Research Hospital, Istanbul, Turkey. Electronic address: dratillacelik@gmail.com.
authors.forename: Atilla
authors.initials: A
authors.lastname: Celik
authors.forename: Ersin
authors.initials: E
authors.lastname: Ergun
authors.forename: Neset
authors.initials: N
authors.lastname: Koksal
authors.forename: Aysun Simsek
authors.initials: AS
authors.lastname: Celik
authors.forename: Ediz
authors.initials: E
authors.lastname: Altinli
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Uzun
authors.forename: Ersan
authors.initials: E
authors.lastname: Eroglu
authors.forename: Ahu
authors.initials: A
authors.lastname: Kemik
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000410:Alanine Transaminase / Q000097:blood; D000714:Anastomosis, Surgical; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D053148:Caspase 3 / Q000378:metabolism; D002374:Catalase / Q000097:blood; D003106:Colon / Q000098:blood supply* / Q000378:metabolism / Q000601:surgery; D003521:Cyclopropanes; D005978:Glutathione / Q000097:blood; D006909:Hydroxyproline / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood; D020024:Leukotriene Antagonists / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D023421:Models, Animal; D009569:Nitric Oxide / Q000097:blood; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D013440:Sulfides; D013482:Superoxide Dismutase / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D015850:Interleukin-6; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D008315:Malondialdehyde; D002374:Catalase; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D053148:Caspase 3; D005978:Glutathione; C093875:montelukast; D006909:Hydroxyproline
keywords: Colon anastomoses; Ischemia/reperfusion; Montelukast